'My staff are involved in setting the global healthcare agenda:' interview with Parexel's Thomas Senderovitz

8 December 2014

With so many balls to juggle in the development pathway of a new drug, pharma companies looking for support along the research process often find value in calling upon the expertise of contract research organizations. Companies such as Parexel (Nasdaq: PRXL), which has recently opened a new European hub near Berlin, Germany, can smooth the patchwork of trials and development by reducing the number of interfaces.

Thomas Senderovitz, senior vice president of clinical research services at Parexel, describes the services that contract research organizations such as Parexel supply as “helping clients make the journey from ideas to the market with more integrated solutions.”

Parexel’s new Berlin-Schönefeld site

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK